ArticleBritish journal of cancer2026
Clinical significance of circulating macrophage markers across different stages of prostate cancer: highlighting soluble CD163.
Article in British journal of cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe clinical significance of circulating macrophage markers in prostate cancer (PC) is largely unexplored. Here, we hypothesised that serum levels of the macrophage markers CD163 and SIRPα might be associated with disease aggressiveness and hold prognostic potential in PC, where novel prognostic biomarkers are needed.
methodsSoluble CD163 (sCD163) and SIRPα (sSIRPα) were measured in serum by enzyme-linked immunosorbent assays in three PC cohorts representing different disease stages (N = 646 patients in total). Prognostic results in metastatic castration-resistant PC (mCRPC) were validated in an independent cohort (N = 161).
resultsSerum levels of sCD163 and sSIRPα were significantly higher in patients with metastatic vs localised PC (p < 0.05). In general, serum sCD163 and sSIRPα levels were not associated with clinical parameters of disease aggressiveness in patients with hormone-sensitive PC (p > 0.05). In mCRPC, high serum sCD163 levels predicted shorter progression-free survival (PFS) on first-line treatment independent of standard clinical parameters in both the training and validation cohort (training: HR: 1.77 (1.12-2.78), p = 0.014; validation: HR: 1.85 (1.15-2.97), p = 0.011).
conclusionsCirculating levels of sCD163 and sSIRPα were increased in patients with metastatic compared to localised PC. Further, higher sCD163 levels predicted worse PFS in mCRPC, suggesting potential as a future minimally-invasive biomarker to aid mCRPC prognostication.
Identifiers
42838995What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.